Second World Congress on the Insulin Resistance Syndrome: Hypertension, cardiovascular disease, and treatment approaches

Diabetes Care

Volumn 28, Issue 8, 2005, Pages 2073-2080

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; APOLIPOPROTEIN B100; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CARBON 13; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FIBRIC ACID DERIVATIVE; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LIPOPROTEIN LIPASE; METFORMIN; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RAMIPRIL; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TROGLITAZONE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; FAT INTAKE; FEMALE; HEART RATE; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; POSITIVE END EXPIRATORY PRESSURE; REVIEW; SLEEP APNEA SYNDROME; SODIUM INTAKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; HEART DISEASES; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X;

EID: 23044473352     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.8.2073     Document Type: Review

References (49)

1. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S: Insulin resistance in essential hypertension. N Engl J Med 317:350-357, 1987
2. Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO: Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 21:618-623, 1993
3. DeFronzo RA, Goldberg M, Agus ZS: The effects of glucose and insulin on renal electrolyte transport. J Clin Invest 58:83-90, 1976
4. Galletti F, Strazzullo P, Ferrara I, Annuzzi G, Rivellese AA, Gatto S, Mancini M: NaCl sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens 15:1485-1491, 1997
5. Sharma AM, Schorr U, Distler A: Insulin resistance in young salt-sensitive normotensive subjects. Hypertension 21:273-279, 1993
6. Verma S, Bhanot S, McNeill JH: Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats. Am J Physiol 267: H1250-H1253, 1994
7. Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D'Onofrio F: Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387-1390, 1993
8. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA: Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 96:354-360, 1995
9. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B, the HOPE Study Investigators: Ramipril and the development of diabetes. JAMA 286: 1882-1885, 2001
10. Scheen AJ: VALUE: analysis of results (Letter). Lancet 364:932-933, 2004
11. Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109:2054-2057, 2004
12. Weiss R, Dufour S, Taksali SE, Tamborlane WV, Petersen KF, Bonadonna RC, Boselli L, Barbetta G, Allen K, Rife F, Savoye M, Dziura J, Sherwin R, Shulman GI, Caprio S: Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362:951-957, 2003
13. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC: Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40:609-611, 2002
14. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, Higashiura K, Shimamoto K: Blockade of the renin-angiotensin system decreases adipocyte size wich improvement in insulin sensitivity. J Hypertens 22:1977-1982, 2004
15. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity: European Group for the Study of Insulin Resistance (EGIR). Hypertension 30:1144-1149, 1997
16. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, Ferrannini E: Effect of insulin on uric acid excretion in humans. Am J Physiol 268:E1-E5, 1995
17. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS: A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352:1138-1145, 2005
18. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, Mitchel YB, Pedersen TR, Kjekshus J, the Scandinavian Simvastatin Survival Study (4S): Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27:1735-1740, 2004
19. Reilly MP, Wolfe ML, Rhodes T, Girman C, Mehta N, Rader DJ: Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110:803-809, 2004
20. Ridker PM, Buring JE, Cook NR, Rifai N: C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107:391-397, 2003
21. Ridker PM, Wilson PW, Grundy SM: Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 109:2818-2825, 2004
22. Tenkanen L, Manttari M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation 92: 1779-1785, 1995
23. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
24. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, Wexler L, Wagner S, Papademetriou V, Rutan G, Robins SJ, the VA-HIT Study Group: Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 103:2828-2833, 2001
25. Bezafibrate Infarction Prevention (BIP) Study Investigators: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102: 21-27, 2000
26. Committee of Principal Investigators: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069-118, 1978
27. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162: 2597-604, 2002
28. Sobel BE, Frye R, Detre KM: Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial: Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation 107:636-642, 2003
29. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD: Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 102:1893-900, 2000
30. Heath RB, Karpe F, Milne RW, Burdge GC, Wootton SA, Frayn KN: Selective partitioning of dietary fatty acids into the VLDL TG pool in the early postprandial period. J Lipid Res 44:2065-2072, 2003
31. Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48:83-95, 2005
32. Vgontzas AN, Legro RS, Bixler EO, Grayev A, Kales A, Chrousos GP: Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86:517-520, 2001
33. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
34. Hamdy O, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Caselli A, Caballero AE, Economides PA, Veves A, Horton ES: Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 26:2119-2125, 2003
35. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 109: 2197-202, 2004
36. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC: Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 26:172-178, 2003
37. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, the Rosiglitazone Clinical Trials Study Group: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
38. Hanley AJ, Karter AJ, Festa A, D'Agostino R Jr, Wagenknecht LE, Savage P, Tracy RP, Saad MF, Haffner S, the Insulin Resistance Atherosclerosis Study: Factor analysis of metabolic syndrome using directly measured insulin sensitivity: the Insulin Resistance Atherosclerosis Study. Diabetes 51:2642-2647, 2002
39. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
40. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN: Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28:1024-1031, 1998
41. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, Ibuki M, Tani T, Tanabe K, Nagai K, Shiratori K, Morioka S, Yoshikawa J: Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 146:E5, 2003
42. Choi D, Kim SK, Choi SH, Ko YG, Ahn CW, Jang Y, Lim SK, Lee HC, Cha BS: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27:2654-2660, 2004
43. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
44. Banerji MA, Chaiken RL, Lebovitz HE: Prolongation of near-normoglycemic remission in black NIDDM subjects with chronic low-dose sulfonylurea treatment. Diabetes 44:466-470, 1995
45. Osei K, Rhinesmith S, Gaillard T, Schuster D: Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes. Metabolism 53:414-422, 2004
46. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G: Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29:41-49, 1980
47. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedhelm E, Drexler H: Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44: 362-368, 2004
48. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161, 2004
49. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 109: 1321-1326, 2002